Inmed announces inm-089 intravitreal formulation in the treatment of dry age-related macular degeneration

Inm-089 ivt formulation selected for continued development demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety margin dose ranging studies completed vancouver, british columbia--(newsfile corp. - february 3, 2025) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the selection of an intravitreal ('ivt') formulation for inm-089 as a drug candidate to be utilized in the company's ongoing development program targeting the treatment of dry age-related macular degeneration ('amd'). michael woudenberg, inmed's chief operating officer and senior vice president of chemistry, manufacturing, and controls, commented, "we are encouraged by the recent data demonstrating that inm-089 can be successfully delivered as an ivt formulation, offering several advantages for the continued development of this compound in the treatment of dry amd.
INM Ratings Summary
INM Quant Ranking